Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
Avirup GuhaPrantesh JainMichael G FradleyDaniel LenihanJahir M GutierrezChhavi JainMarcos de LimaJill S Barnholtz-SloanGuilherme H OliveiraAfshin DowlatiSadeer Al-KindiPublished in: Cancer medicine (2021)
In two independent real-world cohorts, combination BRAF/MEK inhibitors were associated with increased CVAEs compared to monotherapy, especially HF, and hypertension.